Parameter
| Biomarker | ST3GAL1 | Full name | ST3 beta-galactoside alpha-2,3-sialyltransferase 1 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Risk prediction, therapeutic targets | ||
| Disease | Esophageal Carcinoma | Disease Subtypes | / | ||
| Organ | Esophagus | Test Sample / Technology Platform | Organization/plasma (MR analysis, Western blotting) | ||
| Pathobiological Mechanisms | It catalyzes the α-2,3 sialylation modification of glycoproteins and glycolipids, changes cell adhesion properties, enhances immune escape and tumor invasion and metastasis, and plays a role by regulating immune checkpoint molecules such as PD-L1 | ||||
| Clinical Availability Status | Clinical study phase: Mendelian randomization analysis confirmed that its high expression increased the risk of ESCC | ||||
| Notes and Dynamics | As key member of the family of sialic acid transaminase, targeted for ESCC glycosylation modification treatment provides a new direction | ||||